Lung cancer can be broadly classified into two categories such as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Non-small cell lung cancer can be further classified into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Squamous non-small cancer develops from the cells lining the airways and is found near the center of the lungs in one of the main airways. Non-small cell lung cancer globally accounts for 85% to 90% of lung cancer, in which adenocarcinoma and squamous cell cancers are responsible for approximately 40% and 30%, respectively. Prominent symptoms of squamous non-small cell lung cancer include excessive coughing, wheezing and shortness of breath, chest pain, and occurrence of blood in sputum. Many physicians misunderstood this disease with collapsed lungs or pneumonia. The disease usually takes longer time to develop from confined tumors to invasive cancer. Primary diagnostic technique comprises sputum test, bronchoscopy, MRI scan, needle biopsy, and CT scan among others. In Australia, squamous non-small cell lung cancer is a common type of lung cancer accounting for 29% of total cases of lung cancer.
A key factor leading to squamous non-small cell lung cancer is smoking. Besides smoking, secondary risk factors comprise family history, age, and occupational hazards such as minerals and metal dust or exposure to asbestos or radon. Cancer stage detection is a crucial aspect for deterring the patient’s treatment plan. Stage 1 detection is when the squamous cell cancer is small and confined to the lungs, and stage 4 detection is when the tumors have spread beyond tissues and organs near the lungs. Stages between 2 and 3 describe the conditions in between these two extremes. When the squamous non-small cell lung cancer spreads, it may travel to the liver, adrenal glands, bone, brain, and small intestine. Clinical trials and researches conducted by major players are the key growth attributors of the global squamous non-small cell lung cancer market. Some of the prominent pipelined drugs in the market include apatorsen from OncoGenex Pharmaceuticals, famitinib maleate by Jiangsu Hengrui Medicine Co., dacomitinib from Pfizer, etc.
Geographically, in terms of revenue and clinical trials are primarily contributed by the developed economic countries such as North America and European countries. Pertaining to government support, research funding and awareness among people with respect to squamous non-small cell lung cancer are some of the key drivers for the developed economic countries. Asia Pacific is a promising region for the squamous non-small cell lung cancer market. In India, approximately 63,000 new lung cancer cases are reported every year and, astonishingly, a significant proportion of these are patients who have no history in smoking. Among female patients, the prime cause of squamous non-small cell lung cancer is regular exposure to smoke from wood or other substitutes for cooking food. Apart from this occupational health hazards are another prime reason for step rise in female lung cancer in Asian countries. Latin America and African countries in terms of revenue is still at nascent stage but due reforms in healthcare infrastructure, lot of pharmaceutical giants have stated focusing on establishing and increasing customer base in the Middle-East countries as well.
Key players in the squamous non-small cell lung cancer market include AstraZeneca plc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., OncoGenex Pharmaceuticals, Novartis International AG, and Boehringer Ingelheim GmbH.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.